Glucagon-like peptide-1 (GLP-1) receptor agonist initiation is relatively common after bariatric surgery, occurring among about 1 in 10 individuals within 5 years, with influential factors including sex, type of surgery, diabetes status, and postsurgical weight outcomes, according to study results published in JAMA Surgery. GLP-1 initiation was identified using RxNorm codes for semaglutide, liraglutide, tirzepatide, exenatide, lixisenatide, and dulaglutide. “ In this retrospective cohort study using a national multicenter database of electronic health records, approximately 1 in 10 individuals undergoing bariatric surgery initiated a GLP-1. GLP-1 initiation was more frequent among younger patients, women, Black patients, and those undergoing sleeve gastrectomy vs Roux-en-Y gastric bypass. The study authors concluded, “In this retrospective cohort study using a national multicenter database of electronic health records, approximately 1 in 10 individuals undergoing bariatric surgery initiated a GLP-1.”